Trial Profile
A Phase 1, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study in Healthy Subjects and Multiple Ascending Dose Study of CNTO 7160 in Subjects With Asthma and Subjects With Atopic Dermatitis
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Melrilimab (Primary)
- Indications Asthma; Atopic dermatitis
- Focus Adverse reactions; First in man
- Sponsors Janssen Research & Development
- 15 May 2020 Results published in the British Journal of Clinical Pharmacology
- 21 Apr 2017 Status changed from active, no longer recruiting to completed.
- 14 Mar 2017 Planned primary completion date changed from 1 Feb 2017 to 17 Mar 2017.